Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore

[GlobeNewswire] – NATICK, Mass. — Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets … more

View todays social media effects on KPTI

View the latest stocks trending across Twitter. Click to view dashboard

See who Karyopharm is hiring next, click here to view